Tibotec Therapeutics

Dear Healthcare Professional:

Tibotec Therapeutics, in cooperation with the U.S. Food and Drug Administration, would like to inform you of an important safety update to the Severe Skin Reactions WARNINGS AND PRECAUTIONS section (5.1) of the INTELENC...

Yardley, Pa. -- Tibotec Pharmaceuticals Ltd. announced today the opening of its expanded access program (EAP) for its investigational protease inhibitor (PI), TMC114, in the U.S. The program will provide access for HIV-1 infected patients who need th...